Challenges in Artificial Intelligence and Pharmaceutical Supply Chain Integration
The risks of integrating artificial intelligence into legacy infrastructures, data fragmentation, and GxP compliance processes are evaluated by industry experts.
The addition of artificial intelligence technologies on top of legacy systems in pharmaceutical supply chains brings significant challenges such as data fragmentation, auditability issues, and GxP compliance risks.
Challenges of Existing Infrastructures
Integrating artificial intelligence technologies into well-established pharmaceutical supply chain systems reveals various technical barriers, such as data fragmentation and system incompatibility stemming from existing infrastructures.
Industry experts state that layering artificial intelligence directly onto legacy software complicates decision-making processes in areas where GxP compliance is mandatory.
Data Reliability and Auditing
Potential margins of error and limited auditability in artificial intelligence applications pose critical risks regarding the safe shipment of pharmaceuticals.
Mark Talens, Commercial Director at PAXAFE, emphasizes that auditable human intelligence is essential to close data and security gaps.
Real-Time Data and Cold Chain
End-to-end contextualization of real-time data, such as weather conditions, political events, and route disruptions, supports products transported along the cold chain.
The effective use of quality data sources enables instant and accurate decision-making in pharmaceutical logistics.
Human Oversight and Security Boundaries
During the advancement of artificial intelligence automation, clear boundaries must be drawn between areas where the system has direct authority and situations where it only provides recommendations.
Auditing artificial intelligence and maintaining human supervision are vital for building trust and safely deploying automation.